Eli Lilly retatrutide clinical development and regulatory approval
The developments in this story so far, ordered by when they happened.
-
· Development
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
-
Date unknown · Background
Completion of five late-stage clinical trials for retatrutide.
No separate article for this desk or language yet.